<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Adherence to Antiretroviral Therapy and Virologic Failure</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
				<availability status="unknown"><p>Copyright Ovid Technologies (Wolters Kluwer Health)</p>
				</availability>
				<date type="published" when="2016-04">2016-04</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>BPharm, MSc</roleName><forename type="first">Woldesellassie</forename><forename type="middle">M</forename><surname>Bezabhe</surname></persName>
							<email>mwoldesellassie@yahoo.com</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Pharmacy</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution">University of Tasmania</orgName>
								<address>
									<settlement>Tasmania</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Division of Pharmacy</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution">University of Tasmania</orgName>
								<address>
									<settlement>Hobart TAS</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Leanne</forename><surname>Chalmers</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Pharmacy</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution">University of Tasmania</orgName>
								<address>
									<settlement>Tasmania</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Luke</forename><forename type="middle">R</forename><surname>Bereznicki</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Pharmacy</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution">University of Tasmania</orgName>
								<address>
									<settlement>Tasmania</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Gregory</forename><forename type="middle">M</forename><surname>Peterson</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Pharmacy</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution">University of Tasmania</orgName>
								<address>
									<settlement>Tasmania</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Adherence to Antiretroviral Therapy and Virologic Failure</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Medicine</title>
						<title level="j" type="abbrev">Medicine</title>
						<idno type="ISSN">0025-7974</idno>
						<imprint>
							<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
							<biblScope unit="volume">95</biblScope>
							<biblScope unit="issue">15</biblScope>
							<biblScope unit="page">e3361</biblScope>
							<date type="published" when="2016-04" />
						</imprint>
					</monogr>
					<idno type="DOI">10.1097/md.0000000000003361</idno>
					<idno type="PMID">27082595</idno>
					<idno type="PMCID">PMC4839839</idno>
					<note type="submission">Received: November 23, 2015; revised: March 15, 2016; accepted: March 16, 2016.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-14T00:06+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
				<p>The often cited need to achieve !95% (nearly perfect) adherence to antiretroviral therapy (ART) for successful virologic outcomes in HIV may present a barrier to initiation of therapy in the early stages of HIV. This meta-analysis synthesized 43 studies (27,905 participants) performed across &gt;26 countries, to determine the relationship between cutoff point for optimal adherence to ART and virologic outcomes. Meta-analysis was performed using a random-effect model to calculate pooled odds ratios with corresponding 95% confidence intervals. The mean rate of patients reporting optimal adherence was 63.4%. Compared with suboptimal adherence, optimal adherence was associated with a lower risk of virologic failure (0.34; 95% CI: 0.26-0.44). There were no significant differences in the pooled odds ratios among different optimal adherence thresholds (!98-100%, !95%, !80-90%). Study design (randomized controlled trial vs observational study) (regression coefficient 0.74, 95% CI: 0.04-1.43, P &lt; 0.05) and study region (developing vs developed countries; regression coefficient 0.56, 95% CI: 0.01-1.12, P &lt; 0.05) remained as independent predictors of between-study heterogeneity, with more patients with optimal adherence from developing countries or randomized controlled trials experiencing virologic failure. The threshold for optimal adherence to achieve better virologic outcomes appears to be wider than the commonly used cutoff point (!95% adherence). The cutoff point for optimal adherence could be redefined to a slightly lower level to encourage the prescribing ART at an early stage of HIV infection. (Medicine 95(15):e3361) Abbreviations: AIDS = acquired immunodeficiency syndrome, ART = antiretroviral therapy, CAM = comprehensive meta-Analysis, HDI = United Nations human development index, HIV = human immunodeficiency virus, MEMS = medication event monitoring system, NNRTIs = nonnucleoside reverse transcriptase inhibitors, NRTIs = nucleoside/nucleotide reverse transcriptase inhibitors, PIs = protease inhibitors, PRISMA = preferred reporting items for systematic reviews and meta-analyses, RevMan = review manager, RNA = ribonucleic acid, SD = standard deviation. Search Strategy WB carried out systematic literature searches of the electronic databases MEDLINE via PubMed, Cochrane Clinical Trials, and EMBASE from their inception date to 17 April 2015. This search used combinations of the following key words: medication adherence, patient compliance, antiretroviral therapy, antiretroviral agent, antiretroviral treatment, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, virologic failure, and viral load. The reference lists of all articles included in this meta-analysis were also searched. Review articles, editorials, commentaries, government reports, and guidelines were excluded from this review. Titles and abstracts</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p>H IV/AIDS has been transformed into a manageable chronic disease with the advent of combination antiretroviral therapy (ART) initiated as the standard of care. <ref type="bibr" target="#b0">1</ref> Three classes of HIV medications have been widely used in combinationnucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). <ref type="bibr" target="#b0">1</ref> Despite the availability of effective treatment options, suboptimal adherence to treatment can result in insufficient viral suppression and promote the emergence of drug-resistant viral strains, resulting in regimen failure, progression to AIDS, and death. <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref> Paterson et al suggested that at least 95% adherence to unboosted PIs was required for virologic suppression. <ref type="bibr" target="#b4">5</ref> This 95% adherence cut-off point, based on what is now obsolete therapy, has been widely used as the level of optimal adherence needed to be met by patients taking newer agents and their combinations. The concern that patients may not achieve a near-perfect adherence presents a barrier for initiation of therapy in the early stages of HIV. <ref type="bibr" target="#b5">6</ref> This meta-analysis integrated finding from observational studies on ART adherence with 2 objectives: (a) to critically evaluate the association between optimal adherence to ART and virologic outcomes, and (b) to use meta-regression to determine methodological, regimen, and population factors that could moderate the relationship between adherence and virologic outcomes.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head><p>We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement in conducting this meta-analysis. <ref type="bibr" target="#b6">7</ref> Studies eligible for inclusion were randomized controlled trials, retrospective analyses of data from trials, and cohort studies measuring the relationship between medication adherence to ART and virologic failure. of potentially relevant articles were screened independently by WB and YM. Full articles of potentially appropriate citations were screened for inclusion in this review if they fulfilled the following criteria: original research, participants aged 16 years or older, having a clear definition of medication adherence measurement and clear cut-off points for optimal and suboptimal adherence, and virologic failure stratified by optimal and suboptimal medication adherence groups. Ethical approval was not required as this study was based on published data and had no direct access to patient information.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data Collection and Outcome Measures</head><p>WB extracted data using standardized forms, with recording of authors, year of publication, country of study, study type, regimen, method of adherence measurement, cut-off points for good adherence, and virologic failure. The data were verified by a second reviewer (YM). Disagreements between reviewers were resolved through discussion until a consensus was reached. Study authors' grouping of patients into optimal and suboptimal adherence using the most objective measure was used. When a study reported &gt;1 adherence measurement, the most reliable adherence measurement data was used, with reliability defined in following order: medication event monitoring system (MEMS) &gt; pill count &gt; pharmacy refill &gt; self-reported adherence in the past week &gt; self-reported adherence in the past month. When the number of virologic failures within each adherence group was not reported, we calculated virologic failure from the information provided in the paper or contacted the corresponding author. Studies were excluded when it was not possible to obtain virologic failure data in each adherence group. The United Nations Human Development Index (HDI) ranking was used to categories studies into low and high human development groups. <ref type="bibr" target="#b7">8</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analyses</head><p>The data were analyzed using Review Manager (RevMan) version 5.3 (Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, 2014) and Comprehensive Meta-Analysis (CAM) version 3.3.070 (Biostat, Englewood, NJ). Each class of antiretroviral was considered in a separate analysis of the association between adherence and virologic failure in randomized clinical trials. Results are presented based on 9 categories, including study region, antiretroviral regimen, treatment experience, virologic failure cut-off points, adherence cut-off points, adherence measurement, study design, observation period, and year of publication. Adherence pooled odds ratios and 95% confidence intervals were calculated using a random effect model (DerSimonian and Lard) <ref type="bibr" target="#b8">9</ref> that accommodated the random variation within studies and between-studies. <ref type="bibr" target="#b9">10</ref> Heterogeneity between-studies were examined using the Q and I 2 statistics. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b10">11</ref> The odds ratio was plotted against the inverse of standard error to identify the risk of publication bias by visually assessing the symmetry of funnel plots. Statistical significance was confirmed using Egger's test, <ref type="bibr" target="#b11">12</ref> with a P value &lt;0.05 considered suggestive of publication bias. A metaregression was performed to examine major moderators of the between-studies heterogeneity. Results with P values &lt;0.1 from univariate analyses were included in the multivariate meta-regression model.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p>Overall, 1796 studies were identified, of which 1449 were excluded after review of the title and abstract <ref type="figure" target="#fig_0">(Figure 1</ref>). The full text of the remaining 347 citations was screened, and 43 studies with 27,905 participants met the inclusion criteria. The included studies had wide a variation in sample sizes (range ¼ 34-3607, mean ¼ 649, SD ¼ 805) and a slight majority of participants were men (57%). Twenty-five studies were prospective studies <ref type="bibr" target="#b4">5,</ref> that reported virologic failure according to adherence group. The remaining studies were randomized controlled trials (11) <ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref> and retrospective studies (7). <ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref><ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref><ref type="bibr" target="#b53">[54]</ref> Characteristics of the included studies are shown in <ref type="table" target="#tab_1">Table 1</ref>.</p><p>With respect to location, 14 studies were conducted in sub-Saharan Africa; 9 in the US; 6 in Canada; 5 in Europe; 5 in Asia; 1 in Australia; and 3 studies in several countries. Twenty-two (49%) studies included only treatment-naive patients and the remaining 21 studies included both treatment-naive and/or treatment-experienced patients. All studies reported cut-off points for optimal adherence and virologic failure. Thirty studies (70%) defined optimal adherence as !95%, with the remainder using 100%, 98%, 90%, 85%, and 80% as the cut-off points. Optimal adherence rates varied greatly across studies, partially due to the use of these different cut-off points and also different methods of measurement to assess adherence. The mean rate of achieving optimal adherence in adults was 63.4% (standard deviation [SD] ¼ 23.7, range 5% to 97%, n ¼ 43).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Meta-analysis and Meta-regression</head><p>Of a total 27,905 participants, 22,740 participants had a viral load and adherence measurement; 7056 (31%) had virologic failure. Overall, 3464 of 15,067 participants with optimal adherence to ART (23%), and 3592 of 7673 participants with suboptimal adherence (47%) participants had virologic failure ( <ref type="figure" target="#fig_1">Figure 2</ref>). The pooled odds ratio for virologic failure for optimal adherence compared to suboptimal adherence was 0.34 (95% CI: 0.26-0.44). A high degree of heterogeneity was found: Q statistic P &lt; 0.001 and I 2 ¼ 90%. The funnel plot did not show asymmetry ( <ref type="figure" target="#fig_3">Figure 3</ref>), and the result of Egger's test was not statistically significant (P ¼ 0.68). We conducted subgroup analyses to recalculate the pooled odds ratio according to study design, HDI rank, regimen, treatment experience, viral load cut-off points, adherence measurement, and adherence cut-off points ( <ref type="table" target="#tab_3">Table 2)</ref>.</p><p>The results of univariate meta-regression analyses for different moderators are shown in <ref type="table" target="#tab_4">Table 3</ref>. Based on virologic failure cut-off points, studies were classified into three sets including: 100 copies/mL, 11 studies (N ¼ 5646); between 100 copies/mL and 400 copies/mL, 17 studies (N ¼ 9351); and between 500 copies/mL and 1000 copies/mL, 14 studies (N ¼ 7383). The pooled odds ratio for virologic failure for optimal adherence compared to suboptimal adherence for the studies with the lowest virologic failure cut-off was higher (0.55; 95% CI: 0.41-0.74, I 2 ¼ 56%) than for the studies with an intermediate virologic failure cut-off (0.37; 95% CI: 0.26-0.54, I 2 ¼ 88%). The group using a virologic failure cut-off &gt;500 copies/mL had the lowest pooled odds ratio for virologic failure (0.25; 95% CI: 0.16-0.41, I 2 ¼ 92%). Studies with the lowest virologic failure cut-off reported a significantly different pooled odds ratio compared with studies with a virologic failure cut-off &gt; 500 copies/mL (regression coefficient À0.75; 95% CI: À1.39 to À0.12, P ¼ 0.02).</p><p>According to participants' treatment experience, studies were grouped into 3 sets: treatment-naive patients only, 22 studies (N ¼ 17,010); treatment-experienced patients only, 12 studies (N ¼ 4009), and both treatment-naive and experienced patients, 9 studies (N ¼ 1721). The pooled odds ratio for optimal adherence compared to suboptimal adherence for virologic failure for treatment-experienced patients was the highest <ref type="table" target="#tab_3">(Table 2)</ref>; however, no statistically significant difference in pooled odds ratio was found between the 3 groups.</p><p>The relationship between adherence and virologic outcomes varied with type of adherence measurement. The pooled odds ratio for the self-report adherence measure (0.45; 95% CI: 0.37-0.55, I 2 ¼ 31%) was higher than the pooled odds ratio for the pharmacy refill (0.29; 95% CI: 0.20-0.41, I 2 ¼ 94%). The group using MEMS adherence measure had the lowest pooled odd ratio (0.15; 95% CI: 0.06-0.37, I 2 ¼ 35%) for optimal adherence compared to suboptimal adherence for virologic failure. There was a trend toward significant difference across the odds of virologic failure between self-report and MEMS (regression coefficient À1.00; 95% CI: À2.05, 0.06, P ¼ 0.06), but not between self-report and pharmacy refill (regression coefficient À0.22; 95% CI: À0.78, 0.34, P ¼ 0.45).</p><p>The pooled odds ratios were also estimated by grouping studies using cut-off points for optimal adherence studies with a cut-off point between 98% and 100%, 7 studies (N ¼ 3940); studies with a cut-off point of !95%, 30 studies (N ¼ 17,779); and studies with a cut-off point of 80% to 90%, 6 studies (N ¼ 1021). The pooled odds ratios for virologic failure for optimal adherence compared to suboptimal adherence for each cut-off point were similar, with no statistically significant differences.</p><p>The pooled odds ratio for optimal adherence compared to suboptimal adherence for observational studies was significantly greater than randomized controlled studies (regression coefficient, 0.66; 95% CI: 0.10, 1.21, P ¼ 0.02). Studies were aggregated into three subgroups according to HIV-medication regimens: NNRTI-based, boosted PI-based, and unboosted PIbased. The pooled odds ratio for virologic failure for optimal adherence compared to suboptimal adherence for patients taking NNRTI-containing regimens was the highest, but the differences in pooled odds ratios between the regimens were not statistically significant.</p><p>Studies were subgrouped into 2 groups based on the HDI of the country in which the study was performed: very high HDI, 21 studies (N ¼ 10,466); low HDI, 19 studies (N ¼ 9945). The pooled odds ratio for optimal adherence compared to suboptimal adherence for countries with low HDI (0.50; 95% CI: 0.35-0.72) was significantly higher than countries with very high HDI (0.23; 95% CI: 0.15-0.33).</p><p>A multivariate meta-regression model was built-in to examine the specific moderators of the between-study heterogeneity, including the following: study region, threshold used to define virologic failure, adherence measurement, study design,  and year of publication. Study design (observational study versus randomized controlled trials; regression coefficient 0.74, 95% CI: 0.04-1.43, P &lt; 0.05) and study region (developed versus developing countries; regression coefficient 0.56, 95% CI: 0.01-1.12, P &lt; 0.05) remained as independent predictors of between-study heterogeneity.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p>This meta-analysis of 43 studies, involving 27,905 participants, addresses a gap in the current HIV treatment adherence literature with a quantitative evaluation of the association between level of adherence and virologic outcomes among  <ref type="bibr" target="#b41">42</ref> Australia Randomized controlled trial !50 Self-report 100 52 months Cohen et al 2013 <ref type="bibr" target="#b42">43</ref> 21 countries Randomized controlled trial !50 Self-report &gt;95 96 weeks Haubrich et al 1999 <ref type="bibr" target="#b43">44</ref> USA Randomized controlled trial &lt;500 Self-report !95 6 months Muyingo et al 2008 <ref type="bibr" target="#b44">45</ref> Uganda and Zimbabwe adults taking ART. This study revealed that adherence levels as low as 80% to 90% may be adequate for viral suppression in patients taking newer antiretroviral drugs. Our data also showed that pooled odds ratios for virologic failure for optimal adherence compared to suboptimal adherence were similar between NNRTI-based and boosted PI-based regimens. The effectiveness of newer antiretroviral agents at the lower level of adherence may encourage the prescribing of ART at an early stage of HIV infection. The findings indicated that the mean proportion of patients who were reported to demonstrate optimal adherence worldwide was 63.4%, which is similar to a meta-analysis of 84 studies that reported 62% of patients take !90% of their prescribed ART. <ref type="bibr" target="#b54">55</ref> The results of this study demonstrate that adherence is robustly associated with virologic outcomes across the various types of adherence measure, ART regimen, study population, and reporting. The odds of virologic failure were almost 3 times higher for participants with suboptimal adherence compared with those with optimal adherence. This confirms that achieving long-term optimal adherence is indeed Achilles' heel of successful virologic outcomes. <ref type="bibr" target="#b55">56</ref> The need for   clinicians to exert concerted efforts to maintain continuing optimal adherence to antiretroviral therapy is indisputable. Classifying patients according to various optimal adherence thresholds (!98-100%, !95%, and 80-90%) did not result in statistically significant differences in the odds of virologic failure. This finding is consistent with a meta-analysis of 37 studies in children that reported no significant group differences in virologic outcomes between different thresholds of good adherence. <ref type="bibr" target="#b56">57</ref> This suggests that patients who achieved ''perfect'' (100%) or ''near perfect'' (!95%) adherence did not necessarily have better virologic outcomes than patients who had achieved ''good enough'' (!80-90%) adherence. This finding has clinical importance and is in line with previous studies <ref type="bibr" target="#b57">58,</ref><ref type="bibr" target="#b58">59</ref> that indicated that although the need to maintain high levels of adherence to achieve long-term virologic suppression is clear, the level of adherence behavior capable of sustaining viral suppression is broader than previously thought.</p><p>Considerable variation in the relationship between adherence and virologic outcomes was found based on the type of adherence measurement used in the studies we reviewed. For studies using self-reported adherence, the odds of virologic failure in participants with optimal adherence was about half that of participants with suboptimal adherence. The odds of virologic failure for optimal adherence were about one-third and one-seventh that of the participants with suboptimal adherence using pharmacy refill and MEMS, respectively. Our metaanalysis undermines the validity of using self-reported adherence to distinguish virologic outcomes. A high proportion of patients with optimal self-reported adherence experienced virologic failure. Self-reported adherence is potentially confounded by social desirability and recall bias, which leads patients to overestimate their actual adherence; <ref type="bibr" target="#b59">60</ref> this method is inferior to MEMS in its ability to explain virologic outcomes.</p><p>Despite the findings <ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b60">61</ref> of previous studies suggesting the need for different levels of optimal adherence between antiretroviral regimens for achieving similar virologic outcomes, classifying patients based on regimen did not result in statistically significant differences in the odds of virologic outcomes in this meta-analysis.</p><p>The pooled odds ratio for optimal adherence compared to suboptimal adherence for virologic failure for studies with virologic failure cut-offs &lt; 100 copies/mL were significantly higher than studies with virologic failure cut-offs between 500 copies/mL and 1000 copies/mL. The rate of virologic failure detected in patients with good adherence increased when studies defined a virologic failure at a low level of HIV-1 ribonucleic acid (RNA). The relationship between adherence and viral load improved when the level of detection of HIV-1 RNA increased. The tighter the definition of virologic failure the more likely it is to unmask suboptimal adherence. The odds of virologic failure for optimal adherence were about half and one-third that of the patients with suboptimal adherence in countries with a low HDI and high HDI, respectively. More patients with optimal adherence experienced virologic failure in countries with low HDI than in countries with high HDI. This review indicates that patients with equal or better levels of optimal adherence in developing countries compared to developed countries <ref type="bibr" target="#b61">62</ref> does not necessarily translate into better virologic outcomes. This might be associated with the increase in pretreatment antiretroviral drug resistance <ref type="bibr" target="#b62">63</ref> and unavailability of baseline HIV drug resistance testing before initiation of ART 64 in resource-limited settings that have a potential to contribute to the increasing rates of virologic failure in optimally adherent patients. We support moves toward the use viral load monitoring at the point of care in resource-limited settings <ref type="bibr" target="#b64">65</ref> to improve treatment outcomes.</p><p>Study design (observational study vs randomized controlled trials) was an independent predictor of between-study heterogeneity. More patients with optimal adherence experienced virologic failure in randomized controlled trials than in observational studies. Differences in estimated magnitude of treatment effect are very common between randomized controlled trials and observational studies. <ref type="bibr" target="#b65">66</ref> This difference in virologic outcomes between study designs might be related with selection bias in observational studies <ref type="bibr" target="#b66">67</ref> and higher quality and rigor of randomized controlled trials.</p><p>This meta-analysis shares the limitations intrinsic to metaanalysis in general and with studies of adherence in particular. We only included studies published in English, so we may have missed studies that were relevant to our research question during the literature search. When the included studies were stratified and analyzed based on regimen, virologic failure cutoff, adherence cut-off and type of adherence measurement, heterogeneity between-studies remained high for most of the subgroups. Because of this high degree of heterogeneity, which was not entirely described either by subgroup analysis or by meta-regression, our pooled results need to be viewed with caution.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSION</head><p>Irrespective of the cut-off point for optimal adherence, our findings support the tenet that optimal adherence to ART is associated with positive clinical outcomes. The threshold for optimal adherence to achieve better virologic outcomes appears to be wider than the commonly used cut-off point (!95% adherence). Though patients taking ART should be instructed to attain !95% adherence, apprehensions of slightly lower adherence should not deter prescribing ART regimens at an early stage of HIV infection. </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIGURE 1 .</head><label>1</label><figDesc>Flow diagram of study selection.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>FIGURE 2 .</head><label>2</label><figDesc>Association between adherence to antiretroviral therapy and virologic failure.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Funnel</head><label></label><figDesc>Plot of Standard Error by Log odds ratio</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>FIGURE 3 .</head><label>3</label><figDesc>Funnel plot for the association between adherence to antiretroviral therapy and virologic failure (P ¼ 0.68 at Egger's test).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE 1 .</head><label>1</label><figDesc>Characteristics of Included Studies in Meta-Analysis of Adherence to Antiretroviral Therapy and Virologic Failure</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Definition of</cell><cell></cell><cell>Cut-off Point</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>Virologic Failure</cell><cell>Adherence</cell><cell>for Optimal</cell><cell>Observation</cell></row><row><cell>Study</cell><cell>Country</cell><cell>Study Type</cell><cell>(Copies/mL)</cell><cell>Measures</cell><cell>Adherence %</cell><cell>Period</cell></row><row><cell>Pasternak et al 2012 37</cell><cell>Netherlands</cell><cell>Randomized controlled trial</cell><cell>!50</cell><cell>MEMSÃ</cell><cell>100</cell><cell>9 months</cell></row><row><cell>Okonjio et al 2012 38</cell><cell>Kenya</cell><cell>Randomized controlled trial</cell><cell>!400</cell><cell>Pill count</cell><cell>!95</cell><cell>24 weeks</cell></row><row><cell>Murphy et al 2012 48</cell><cell>South Africa</cell><cell>Retrospective study</cell><cell>!50</cell><cell>Pharmacy refill</cell><cell>&gt;90</cell><cell>24 months</cell></row><row><cell>Nolan et al 2011 49</cell><cell>Canada</cell><cell>Retrospective study</cell><cell>!500</cell><cell>Pharmacy refill</cell><cell>!95</cell><cell>Median 51 months</cell></row><row><cell cols="2">El-Khatib et al 2011b 50 South Africa</cell><cell>Retrospective study</cell><cell>&gt;50</cell><cell>Pharmacy refill</cell><cell>!95</cell><cell>Median 44 months</cell></row><row><cell>Messou et al 2011 13</cell><cell>Côte d'Ivoire</cell><cell>Prospective study</cell><cell>!300</cell><cell>Pharmacy refill</cell><cell>!95</cell><cell>12 months</cell></row><row><cell>Lima et al 2010 51</cell><cell>Canada</cell><cell>Retrospective study</cell><cell>&gt;400</cell><cell>Pharmacy refill</cell><cell>!95</cell><cell>Median 2 years</cell></row><row><cell>Ford et al 2010 14</cell><cell>South Africa</cell><cell>Prospective study</cell><cell>&gt;5000</cell><cell>Self-report</cell><cell>!95</cell><cell>5 years</cell></row><row><cell>Nellen et al 2009 15</cell><cell>Netherlands</cell><cell>Prospective study</cell><cell>&gt;400</cell><cell>Pharmacy refill</cell><cell>!85</cell><cell>2 years</cell></row><row><cell>San et al 2008 16</cell><cell>Mozambique</cell><cell>Prospective study</cell><cell>!1000</cell><cell>Pill count</cell><cell>&gt;95</cell><cell>1 year</cell></row><row><cell>Nachega et al 2007 17</cell><cell>South Africa</cell><cell>Prospective study</cell><cell>&gt;400</cell><cell>Pharmacy refill</cell><cell>100</cell><cell>Median 2.2 years</cell></row><row><cell>Gross et al 2006 18</cell><cell>Canada</cell><cell>Prospective study</cell><cell>&gt;1000</cell><cell>Pharmacy refill</cell><cell>&gt;95</cell><cell>Median 29 months</cell></row><row><cell>Moore et al 2005 19</cell><cell>Canada</cell><cell>Prospective study</cell><cell>!500</cell><cell>Pharmacy refill</cell><cell>&gt;95</cell><cell>Median 44.7 months</cell></row><row><cell>Kitahata et al 2004 52</cell><cell>USA</cell><cell>Retrospective study</cell><cell>&gt;500</cell><cell>Pharmacy refill</cell><cell>&gt;90</cell><cell>Median 89 weeks</cell></row><row><cell>Cahn et al 2004 39</cell><cell>Argentina, Brazil,</cell><cell>Randomized controlled trial</cell><cell>!400</cell><cell>Self-report</cell><cell>!95</cell><cell>48 weeks</cell></row><row><cell></cell><cell>Mexico, Italy,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Thailand, Canada</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Arnsten et al 2001 20</cell><cell>USA</cell><cell>Prospective study</cell><cell>&gt;500</cell><cell>MEMS</cell><cell>!90</cell><cell>5.1 months</cell></row><row><cell>McNabb et al 2001 21</cell><cell>USA</cell><cell>Prospective study</cell><cell>!400</cell><cell>MEMS</cell><cell>&gt;95</cell><cell>3 months</cell></row><row><cell>Parienti et al 2010 22</cell><cell>USA</cell><cell>Prospective study</cell><cell>!50 (400)</cell><cell>MEMS</cell><cell>&gt;95</cell><cell>2 years</cell></row><row><cell cols="2">Bangsberg et al 2000 23 USA</cell><cell>Prospective study</cell><cell>!400</cell><cell>MEMS</cell><cell>!98</cell><cell>Median 9.4 weeks</cell></row><row><cell>Paterson et al 2000 5</cell><cell>USA</cell><cell>Prospective study</cell><cell>!400</cell><cell>MEMS</cell><cell>!95</cell><cell>Median 6 months</cell></row><row><cell>Tuldra et al 2000 40</cell><cell>Spain</cell><cell>Randomized controlled trial</cell><cell>&gt;400</cell><cell>Self-report</cell><cell>!95</cell><cell>48 weeks</cell></row><row><cell>Meresse et al 2013 41</cell><cell>Cameroon</cell><cell>Randomized controlled trial</cell><cell>!40</cell><cell>Self-report</cell><cell>!80</cell><cell>24 months</cell></row><row><cell>Abah et al 2014 53</cell><cell>Nigeria</cell><cell>Retrospective study</cell><cell>&gt;1000</cell><cell>Pharmacy refill</cell><cell>!95</cell><cell>Median 12 months</cell></row><row><cell>Neogi et al 2013 24</cell><cell>India</cell><cell>Prospective study</cell><cell>&gt;400</cell><cell>Self-report</cell><cell>100</cell><cell>2 years</cell></row><row><cell>Li et al 2012 25</cell><cell>USA</cell><cell>Prospective study</cell><cell>!200</cell><cell>Self-report and</cell><cell>!95</cell><cell>32 months</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Pill count</cell><cell></cell><cell></cell></row><row><cell>McMahon et al 2013 54</cell><cell>India</cell><cell>Retrospective study</cell><cell>!200</cell><cell>Pharmacy refill</cell><cell>&gt;95</cell><cell>12 months</cell></row><row><cell>Ekstrand et al 2011 26</cell><cell>India</cell><cell>Prospective study</cell><cell>&gt;1000</cell><cell>Self-report</cell><cell>!95</cell><cell>2 years</cell></row><row><cell cols="2">Lower-Beer et al 2000 27 Canada</cell><cell>Prospective study</cell><cell>&gt;500</cell><cell>Pharmacy refill</cell><cell>!95</cell><cell>Median 19 months</cell></row><row><cell>Carr et al 2000</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>TABLE 2 .</head><label>2</label><figDesc>Subgroup Analysis Adherence to Antiretroviral Therapy and Virologic Failure United Nations human development index, MEMS ¼ medication event monitoring system, NNRTIs ¼ nonnucleoside reverse transcriptase inhibitors, PIs ¼ protease inhibitors.</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell cols="2">Tests for Heterogeneity</cell></row><row><cell>Analysis Group</cell><cell>No of Studies</cell><cell>Pooled Odds Ratio (95% CI)</cell><cell>P Value (Q Statistic)</cell><cell>I 2 (%)</cell></row><row><cell>Study design</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Randomized controlled trial</cell><cell>11</cell><cell>0.55 (0.33-0.92)</cell><cell>&lt;0.001</cell><cell>85</cell></row><row><cell>Observational study</cell><cell>32</cell><cell>0.29 (0.22-0.38)</cell><cell>&lt;0.001</cell><cell>90</cell></row><row><cell>HDI rank</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>High HDI</cell><cell>21</cell><cell>0.23 (0.15-0.33)</cell><cell>&lt;0.001</cell><cell>91</cell></row><row><cell>Low HDI</cell><cell>19</cell><cell>0.50 (0.35-0.72)</cell><cell>&lt;0.001</cell><cell>87</cell></row><row><cell>Regimen</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>NNRTI-based</cell><cell>17</cell><cell>0.54 (0.38-0.77)</cell><cell>&lt;0.001</cell><cell>88</cell></row><row><cell>Boosted PI-based</cell><cell>4</cell><cell>0.31 (0.14-0.71)</cell><cell>0.06</cell><cell>59</cell></row><row><cell>Unboosted PI-based</cell><cell>5</cell><cell>0.25 (0.13-0.47)</cell><cell>0.11</cell><cell>47</cell></row><row><cell>Treatment experience</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Naive</cell><cell>22</cell><cell>0.33 (0.23-0.47)</cell><cell>&lt;0.001</cell><cell>94</cell></row><row><cell>Experienced</cell><cell>12</cell><cell>0.52 (0.41-0.66)</cell><cell>0.36</cell><cell>9</cell></row><row><cell>Naive and experienced</cell><cell>9</cell><cell>0.28 (0.17-0.46)</cell><cell>0.001</cell><cell>69</cell></row><row><cell cols="2">Threshold used to define virological failure</cell><cell></cell><cell></cell><cell></cell></row><row><cell>100 copies/mL</cell><cell>11</cell><cell>0.55 (0.41-0.74)</cell><cell>0.01</cell><cell>56</cell></row><row><cell>100-400 copies/mL</cell><cell>17</cell><cell>0.37 (0.26-0.54)</cell><cell>&lt;0.001</cell><cell>88</cell></row><row><cell>!500 copies/mL</cell><cell>14</cell><cell>0.25 (0.16-0.41)</cell><cell>&lt;0.001</cell><cell>92</cell></row><row><cell cols="2">Threshold used to define optimal adherence group</cell><cell></cell><cell></cell><cell></cell></row><row><cell>!98-100%</cell><cell>7</cell><cell>0.54 (0.29-1.00)</cell><cell>&lt;0.001</cell><cell>85</cell></row><row><cell>!95%</cell><cell>30</cell><cell>0.34 (0.24-0.47)</cell><cell>&lt;0.001</cell><cell>92</cell></row><row><cell>!80-90%</cell><cell>6</cell><cell>0.34 (0.23-0.51)</cell><cell>0.57</cell><cell>0</cell></row><row><cell>Measurement</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Self-report</cell><cell>14</cell><cell>0.45 (0.37-0.55)</cell><cell>0.13</cell><cell>31</cell></row><row><cell>Pharmacy refill</cell><cell>18</cell><cell>0.29 (0.20-0.41)</cell><cell>&lt;0.001</cell><cell>94</cell></row><row><cell>MEMS</cell><cell>6</cell><cell>0.15 (0.06-0.37)</cell><cell>0.18</cell><cell>35</cell></row><row><cell>Pill count</cell><cell>4</cell><cell>0.80 (0.21-3.02)</cell><cell>&lt;0.001</cell><cell>93</cell></row><row><cell>CI ¼ confidence interval, HDI ¼</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>TABLE 3 .</head><label>3</label><figDesc>Meta-Regression Analysis of Moderators for the Association Between Antiretroviral Adherence and Virologic Failure</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Regression</cell><cell></cell><cell>I 2 Inconsistency</cell></row><row><cell>Moderator</cell><cell>Category 1</cell><cell>Category 2</cell><cell cols="2">Coefficient (95%CI) P Value</cell><cell>Q Statistic</cell></row><row><cell>Region</cell><cell cols="2">Developing countries Developed countries</cell><cell>0.79 (0.25, 1.32)</cell><cell>0.004</cell><cell>89.2%; 352.4 (38 df), P &lt; 0.001</cell></row><row><cell>Regimen</cell><cell>NNRTIs</cell><cell>Boosted PIs</cell><cell>0.58 (À0.42, 1.59)</cell><cell>0.257</cell><cell>88.8%; 349.11 (39 df), P &lt; 0.001</cell></row><row><cell>Treatment experience</cell><cell>Experienced</cell><cell>Naive</cell><cell>0.38 (À0.27, 1.04)</cell><cell>0.250</cell><cell>90.1%; 404.22 (40 df), P &lt; 0.001</cell></row><row><cell>Threshold used to</cell><cell>100-400 copies/mL</cell><cell>100 copies/mL</cell><cell>À0.30 (À0.92, 0.33)</cell><cell>0.353</cell><cell>87.5%; 312.53 (39 df), P &lt; 0.001</cell></row><row><cell>define virologic failure</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>!500 copies/mL</cell><cell>100 copies/mL</cell><cell>À0.75 (À1.39, À0.12)</cell><cell>0.020</cell><cell></cell></row><row><cell>Threshold used to define</cell><cell>!80-90%</cell><cell>!98-100%</cell><cell>À0.56 (À1.62, À0.51)</cell><cell>0.304</cell><cell>90.7%; 430.21 (40 df), P &lt; 0.001</cell></row><row><cell>optimal adherence group</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>!95%</cell><cell>!98-100%</cell><cell>À0.54 (À1.31, 0.23)</cell><cell>0.171</cell><cell></cell></row><row><cell>Measurement</cell><cell>Pharmacy refill</cell><cell>Self-report</cell><cell>À0.22 (À0.78, 0.34)</cell><cell>0.446</cell><cell>90.2%; 398.75 (df 39), P &lt; 0.001</cell></row><row><cell></cell><cell>MEMS</cell><cell>Self-report</cell><cell>À1.00 (À2.05, 0.06)</cell><cell>0.064</cell><cell></cell></row><row><cell></cell><cell>Pill count</cell><cell>Self-report</cell><cell>0.17 (À0.89, 1.24)</cell><cell>0.749</cell><cell></cell></row><row><cell>Study design</cell><cell>RCT</cell><cell>Observational study</cell><cell>0.66 (0.10, 1.21)</cell><cell>0.020</cell><cell>88.7%; 364.17 (41 df), P &lt; 0.001</cell></row><row><cell>Observation period</cell><cell>1 year</cell><cell>&gt;1 year</cell><cell>0.15 (À0.38, 0.69)</cell><cell>0.574</cell><cell>90.1%; 413.84 (31 df), P &lt; 0.001</cell></row><row><cell>Year of publication</cell><cell>!2005</cell><cell>&lt;2005</cell><cell>0.67 (0.07, 1.28)</cell><cell>0.028</cell><cell>89.6%; 394.36 (41 df), P &lt; 0.001</cell></row><row><cell>Multivariate</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Region</cell><cell>Developing countries</cell><cell>Developed</cell><cell>0.56 (0.01, 1.12)</cell><cell>0.048</cell><cell>82.6%; 172.5 (30 df), P &lt; 0.001</cell></row><row><cell>Threshold used to define</cell><cell>!500 copies/mL</cell><cell>100 copies/mL</cell><cell>À0.46 (À1.23, 0.30)</cell><cell>0.238</cell><cell></cell></row><row><cell>virologic failure</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Measurement</cell><cell>MEMS</cell><cell>Self-report</cell><cell>À0.50 (À1.58, 0.58)</cell><cell>0.366</cell><cell></cell></row><row><cell>Study design</cell><cell>RCT</cell><cell>Observational study</cell><cell>0.74 (0.04, 1.43)</cell><cell>0.038</cell><cell></cell></row><row><cell>Year of publication</cell><cell>!2005</cell><cell>&lt;2005</cell><cell>0.43 (À0.37, 1.23)</cell><cell>0.291</cell><cell></cell></row></table><note>MEMS ¼ medication event monitoring system, NNRTIs ¼ nonnucleoside reverse transcriptase inhibitors, PIs ¼ protease inhibitors.</note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="6">| www.md-journal.com Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p>The authors would like to acknowledge Yihienew Mequanint for his assistance in screening articles and verifying the extracted data, and all study authors who responded to inquiries about relevant papers.</p><p>This meta-analysis was conducted in partial fulfillment of a PhD in Pharmacy at School of Medicine, University of Tasmania. The authors received no specific funding for this research.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Frank</forename><forename type="middle">J</forename><surname>Palella</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kathleen</forename><forename type="middle">M</forename><surname>Delaney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anne</forename><forename type="middle">C</forename><surname>Moorman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><forename type="middle">O</forename><surname>Loveless</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jack</forename><surname>Fuhrer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Glen</forename><forename type="middle">A</forename><surname>Satten</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Diane</forename><forename type="middle">J</forename><surname>Aschman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Scott</forename><forename type="middle">D</forename><surname>Holmberg</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejm199803263381301</idno>
		<idno type="PMID">9516219</idno>
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<title level="j" type="abbrev">N Engl J Med</title>
		<idno type="ISSN">0028-4793</idno>
		<idno type="ISSNe">1533-4406</idno>
		<imprint>
			<biblScope unit="volume">338</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="853" to="860" />
			<date type="published" when="1998-03-26" />
			<publisher>New England Journal of Medicine (NEJM/MMS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Delaugerre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Rohban</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Mouroux</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Tricot</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Agher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Huraux</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Katlama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Calvez</surname></persName>
		</author>
		<idno type="DOI">10.1002/jmv.2055</idno>
		<idno type="PMID">11596076</idno>
		<idno type="ark">ark:/67375/WNG-SZF0RGQ9-G</idno>
		<idno type="istexId">ADFF7061882DE3E605D1E7A20F03A78193BE2C96</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Medical Virology</title>
		<title level="j" type="abbrev">J. Med. Virol.</title>
		<idno type="ISSN">0146-6615</idno>
		<idno type="ISSNe">1096-9071</idno>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="445" to="448" />
			<date type="published" when="2001" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Predictors of Virologic Failure and Resistance in HIV-Infected Patients Treated with Nevirapine- or Efavirenz-Based Antiretroviral Therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-J</forename><surname>Parienti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Massari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Descamps</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Vabret</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Bouvet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Larouze</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Verdon</surname></persName>
		</author>
		<idno type="DOI">10.1086/383572</idno>
		<idno type="PMID">15127346</idno>
		<idno type="ark">ark:/67375/HXZ-XHVD9FZ8-G</idno>
		<idno type="istexId">46631D9D4F631D8C5FB2588AB2F7BA8E49FED29E</idno>
		<ptr type="open-access" target="https://academic.oup.com/cid/article-pdf/38/9/1311/904901/38-9-1311.pdf" />
	</analytic>
	<monogr>
		<title level="j">Clinical Infectious Diseases</title>
		<title level="j" type="abbrev">Clinical Infectious Diseases</title>
		<idno type="ISSN">1058-4838</idno>
		<idno type="ISSNe">1537-6591</idno>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1311" to="1316" />
			<date type="published" when="2004-05-01" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Non-adherence to highly active antiretroviral therapy predicts progression to AIDS</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">R</forename><surname>Bangsberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sharon</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Edwin</forename><forename type="middle">D</forename><surname>Charlebois</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">A</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marjorie</forename><surname>Roberston</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">R</forename><surname>Zolopa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><surname>Moss</surname></persName>
		</author>
		<idno type="DOI">10.1097/00002030-200106150-00015</idno>
		<idno type="PMID">11416722</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS</title>
		<title level="j" type="abbrev">AIDS</title>
		<idno type="ISSN">0269-9370</idno>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1181" to="1183" />
			<date type="published" when="2001-06" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">L</forename><surname>Paterson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susan</forename><surname>Swindells</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeffrey</forename><surname>Mohr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michelle</forename><surname>Brester</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Emanuel</forename><forename type="middle">N</forename><surname>Vergis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cheryl</forename><surname>Squier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marilyn</forename><forename type="middle">M</forename><surname>Wagener</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nina</forename><surname>Singh</surname></persName>
		</author>
		<idno type="DOI">10.7326/0003-4819-133-1-200007040-00004</idno>
		<idno type="PMID">10877736</idno>
	</analytic>
	<monogr>
		<title level="j">Annals of Internal Medicine</title>
		<title level="j" type="abbrev">Ann Intern Med</title>
		<idno type="ISSN">0003-4819</idno>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">21</biblScope>
			<date type="published" when="2000-07-04" />
			<publisher>American College of Physicians</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Clinician Practices and Attitudes Regarding Early Antiretroviral Therapy in the United States</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ann</forename><forename type="middle">E</forename><surname>Kurth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kenneth</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Geetha</forename><surname>Beauchamp</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Laura</forename><surname>Mckinstry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jennifer</forename><surname>Farrior</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kate</forename><surname>Buchacz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Deborah</forename><surname>Donnell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bernard</forename><surname>Branson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wafaa</forename><surname>El-Sadr</surname></persName>
		</author>
		<idno type="DOI">10.1097/qai.0b013e31826a184c.</idno>
		<idno type="PMID">23183150</idno>
		<idno type="PMCID">PMC3957230</idno>
		<ptr type="open-access" target="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3957230/pdf" />
	</analytic>
	<monogr>
		<title level="j">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<title level="j" type="abbrev">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<idno type="ISSN">1525-4135</idno>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="e65" to="e69" />
			<date type="published" when="2012-12" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alessandro</forename><surname>Liberati</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Tetzlaff</surname></persName>
		</author>
		<idno type="DOI">10.7326/0003-4819-151-4-200908180-00136</idno>
		<idno type="PMID">19622512</idno>
		<ptr type="open-access" target="http://annals.org/data/journals/aim/20188/0000605-200908180-00136.pdf" />
	</analytic>
	<monogr>
		<title level="j">Annals of Internal Medicine</title>
		<title level="j" type="abbrev">Ann Intern Med</title>
		<idno type="ISSN">0003-4819</idno>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">W</biblScope>
			<date type="published" when="2009-08-18" />
			<publisher>American College of Physicians</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m" type="main">United Nations Development Programme</title>
		<imprint>
			<date type="published" when="2014" />
			<pubPlace>New York, USA</pubPlace>
		</imprint>
	</monogr>
	<note type="report_type">Human development report</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Meta-analysis in clinical trials</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rebecca</forename><surname>Dersimonian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nan</forename><surname>Laird</surname></persName>
		</author>
		<idno type="DOI">10.1016/0197-2456(86)90046-2</idno>
		<idno type="PMID">3802833</idno>
		<idno type="PII">0197-2456(86)90046-2</idno>
		<idno type="ark">ark:/67375/6H6-NQ8X10JN-L</idno>
		<idno type="istexId">57F64D8AA486BA31E66347792B6CA3AC99E9ED32</idno>
	</analytic>
	<monogr>
		<title level="j">Controlled Clinical Trials</title>
		<title level="j" type="abbrev">Controlled Clinical Trials</title>
		<idno type="ISSN">0197-2456</idno>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="177" to="188" />
			<date type="published" when="1986-09" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Fixed- and random-effects models in meta-analysis.</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Larry</forename><forename type="middle">V</forename><surname>Hedges</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jack</forename><forename type="middle">L</forename><surname>Vevea</surname></persName>
		</author>
		<idno type="DOI">10.1037/1082-989x.3.4.486</idno>
	</analytic>
	<monogr>
		<title level="j">Psychological Methods</title>
		<title level="j" type="abbrev">Psychological Methods</title>
		<idno type="ISSN">1082-989X</idno>
		<idno type="ISSNe">1939-1463</idno>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="486" to="504" />
			<date type="published" when="1998" />
			<publisher>American Psychological Association (APA)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Measuring inconsistency in meta-analyses</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">P</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">G</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Deeks</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.327.7414.557</idno>
		<idno type="PMID">12958120</idno>
		<idno type="PMCID">PMC192859</idno>
		<idno type="ark">ark:/67375/NVC-QJDCZCKZ-4</idno>
		<idno type="istexId">643263D3B945EA135ECBEE4BD099C0C6AB6BD09F</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc192859?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<title level="j" type="abbrev">BMJ</title>
		<idno type="ISSN">0959-8138</idno>
		<idno type="ISSNe">1468-5833</idno>
		<imprint>
			<biblScope unit="volume">327</biblScope>
			<biblScope unit="issue">7414</biblScope>
			<biblScope unit="page" from="557" to="560" />
			<date type="published" when="2003-09-06" />
			<publisher>BMJ</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Bias in meta-analysis detected by a simple, graphical test</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Egger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">D</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Minder</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.315.7109.629</idno>
		<idno type="PMID">9310563</idno>
		<idno type="PMCID">PMC2127453</idno>
		<idno type="ark">ark:/67375/NVC-GDHS6BZN-G</idno>
		<idno type="istexId">5C725A55ADC81009B0F9838AE28F5EE6633E6FCC</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc2127453?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<title level="j" type="abbrev">BMJ</title>
		<idno type="ISSN">0959-8138</idno>
		<idno type="ISSNe">1468-5833</idno>
		<imprint>
			<biblScope unit="volume">315</biblScope>
			<biblScope unit="issue">7109</biblScope>
			<biblScope unit="page" from="629" to="634" />
			<date type="published" when="1997-09-13" />
			<publisher>BMJ</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Association Between Medication Possession Ratio, Virologic Failure and Drug Resistance in HIV-1–Infected Adults on Antiretroviral Therapy in Côte dʼIvoire</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eugène</forename><surname>Messou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marie-Laure</forename><surname>Chaix</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Delphine</forename><surname>Gabillard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Albert</forename><surname>Minga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elena</forename><surname>Losina</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vincent</forename><surname>Yapo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martial</forename><surname>Kouakou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christine</forename><surname>Danel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Caroline</forename><surname>Sloan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christine</forename><surname>Rouzioux</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kenneth</forename><forename type="middle">A</forename><surname>Freedberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xavier</forename><surname>Anglaret</surname></persName>
		</author>
		<idno type="DOI">10.1097/qai.0b013e3182084b5a</idno>
		<idno type="PMID">21191309</idno>
		<idno type="PMCID">PMC3050083</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3050083?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<title level="j" type="abbrev">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<idno type="ISSN">1525-4135</idno>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="356" to="364" />
			<date type="published" when="2011-04" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Early Adherence to Antiretroviral Medication as a Predictor of Long-Term HIV Virological Suppression: Five-Year Follow Up of an Observational Cohort</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nathan</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marta</forename><surname>Darder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tim</forename><surname>Spelman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Emi</forename><surname>Maclean</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Edward</forename><surname>Mills</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><surname>Boulle</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0010460</idno>
		<idno type="PMID">20485480</idno>
		<idno type="PMCID">PMC2864744</idno>
		<ptr type="open-access" target="https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0010460&amp;type=printable" />
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<title level="j" type="abbrev">PLoS ONE</title>
		<idno type="ISSNe">1932-6203</idno>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">e10460</biblScope>
			<date type="published" when="2010-05-05" />
			<publisher>Public Library of Science (PLoS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Which method of adherence measurement is most suitable for daily use to predict virological failure among immigrant and non-immigrant HIV-1 infected patients?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeannine</forename><forename type="middle">F J B</forename><surname>Nellen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pythia</forename><forename type="middle">T</forename><surname>Nieuwkerk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">M</forename><surname>Burger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mirte</forename><surname>Wibaut</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Luuk</forename><forename type="middle">A</forename><surname>Gras</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jan</forename><forename type="middle">M</forename><surname>Prins</surname></persName>
		</author>
		<idno type="DOI">10.1080/09540120802612816</idno>
		<idno type="PMID">20024740</idno>
		<ptr type="open-access" target="https://hal.archives-ouvertes.fr/hal-00513479/document" />
	</analytic>
	<monogr>
		<title level="j">AIDS Care</title>
		<title level="j" type="abbrev">AIDS Care</title>
		<idno type="ISSN">0954-0121</idno>
		<idno type="ISSNe">1360-0451</idno>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="842" to="850" />
			<date type="published" when="2009-06-29" />
			<publisher>Informa UK Limited</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Evaluating Adherence to Highly Active Antiretroviral Therapy with Use of Pill Counts and Viral Load Measurement in the Drug Resources Enhancement against AIDS and Malnutrition Program in Mozambique</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Massimo</forename><forename type="middle">Magnano</forename><surname>San Lio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Riccardo</forename><surname>Carbini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paola</forename><surname>Germano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giovanni</forename><surname>Guidotti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sandro</forename><surname>Mancinelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Noorjehan</forename><forename type="middle">Abdul</forename><surname>Magid</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pasquale</forename><surname>Narciso</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Leonardo</forename><surname>Palombi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elsa</forename><surname>Renzi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ines</forename><surname>Zimba</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maria</forename><forename type="middle">Cristina</forename><surname>Marazzi</surname></persName>
		</author>
		<idno type="DOI">10.1086/587659</idno>
		<idno type="PMID">18419498</idno>
		<idno type="ark">ark:/67375/HXZ-LTNF75H1-N</idno>
		<idno type="istexId">BB4443145F3ED0F85C5656FD2D2B0FA7F95F7212</idno>
		<ptr type="open-access" target="https://academic.oup.com/cid/article-pdf/46/10/1609/834932/46-10-1609.pdf" />
	</analytic>
	<monogr>
		<title level="j">Clinical Infectious Diseases</title>
		<title level="j" type="abbrev">CLIN INFECT DIS</title>
		<idno type="ISSN">1058-4838</idno>
		<idno type="ISSNe">1537-6591</idno>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1609" to="1616" />
			<date type="published" when="2008-05-15" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Adherence to Nonnucleoside Reverse Transcriptase Inhibitor–Based HIV Therapy and Virologic Outcomes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jean</forename><forename type="middle">B</forename><surname>Nachega</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><surname>Hislop</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">W</forename><surname>Dowdy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">E</forename><surname>Chaisson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Leon</forename><surname>Regensberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gary</forename><surname>Maartens</surname></persName>
		</author>
		<idno type="DOI">10.7326/0003-4819-146-8-200704170-00007</idno>
		<idno type="PMID">17438315</idno>
	</analytic>
	<monogr>
		<title level="j">Annals of Internal Medicine</title>
		<title level="j" type="abbrev">Ann Intern Med</title>
		<idno type="ISSN">0003-4819</idno>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page">564</biblScope>
			<date type="published" when="2007-04-17" />
			<publisher>American College of Physicians</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">A Simple, Dynamic Measure of Antiretroviral Therapy Adherence Predicts Failure to Maintain HIV‐1 Suppression</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Benita</forename><surname>Yip</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vincent</forename><forename type="middle">Lo</forename><surname>Re iii</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Evan</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christopher</forename><forename type="middle">S</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle"> Richard</forename><surname>Harrigan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">R</forename><surname>Bangsberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julio</forename><forename type="middle">S G</forename><surname>Montaner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">S</forename><surname>Hogg</surname></persName>
		</author>
		<idno type="DOI">10.1086/507680</idno>
		<idno type="PMID">16991085</idno>
		<idno type="ark">ark:/67375/HXZ-HLZG0DM1-C</idno>
		<idno type="istexId">4354C27DACBEFD7380054ACB9EB7D9E9A7F59FFA</idno>
		<ptr type="open-access" target="https://academic.oup.com/jid/article-pdf/194/8/1108/18012519/194-8-1108.pdf" />
	</analytic>
	<monogr>
		<title level="j">The Journal of Infectious Diseases</title>
		<title level="j" type="abbrev">J INFECT DIS</title>
		<idno type="ISSN">0022-1899</idno>
		<idno type="ISSNe">1537-6613</idno>
		<imprint>
			<biblScope unit="volume">194</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1108" to="1114" />
			<date type="published" when="2006-10-15" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy Are Associated With Increased Mortality and Poor Adherence to Therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">M</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">S</forename><surname>Hogg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Benita</forename><surname>Yip</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Evan</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><surname>Tyndall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paula</forename><surname>Braitstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julio</forename><forename type="middle">S G</forename><surname>Montaner</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.qai.0000182847.38098.d1</idno>
		<idno type="PMID">16249702</idno>
	</analytic>
	<monogr>
		<title level="j">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<title level="j" type="abbrev">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<idno type="ISSN">1525-4135</idno>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="288" to="293" />
			<date type="published" when="2005-11" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Antiretroviral Therapy Adherence and Viral Suppression in HIV‐Infected Drug Users: Comparison of Self‐Report and Electronic Monitoring</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julia</forename><forename type="middle">H</forename><surname>Arnsten</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Penelope</forename><forename type="middle">A</forename><surname>Demas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Homayoon</forename><surname>Farzadegan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">W</forename><surname>Grant</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marc</forename><forename type="middle">N</forename><surname>Gourevitch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chee‐jen</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Donna</forename><surname>Buono</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Haftan</forename><surname>Eckholdt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrea</forename><forename type="middle">A</forename><surname>Howard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ellie</forename><forename type="middle">E</forename><surname>Schoenbaum</surname></persName>
		</author>
		<idno type="DOI">10.1086/323201</idno>
		<idno type="PMID">11550118</idno>
		<idno type="PMCID">PMC2692641</idno>
		<idno type="ark">ark:/67375/HXZ-262S3116-D</idno>
		<idno type="istexId">0CB40EB40FA4A3087E954B888CBEEBEC2BF15F89</idno>
		<ptr type="open-access" target="https://academic.oup.com/cid/article-pdf/33/8/1417/997834/33-8-1417.pdf" />
	</analytic>
	<monogr>
		<title level="j">Clinical Infectious Diseases</title>
		<title level="j" type="abbrev">CLIN INFECT DIS</title>
		<idno type="ISSN">1058-4838</idno>
		<idno type="ISSNe">1537-6591</idno>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1417" to="1423" />
			<date type="published" when="2001-10-15" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Adherence to Highly Active Antiretroviral Therapy Predicts Virologic Outcome at an Inner‐City Human Immunodeficiency Virus Clinic</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jocarol</forename><surname>Mcnabb</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jack</forename><forename type="middle">W</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kenneth</forename><surname>Abriola</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christina</forename><surname>Turley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Charles</forename><forename type="middle">H</forename><surname>Nightingale</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">P</forename><surname>Nicolau</surname></persName>
		</author>
		<idno type="DOI">10.1086/322590</idno>
		<idno type="PMID">11486292</idno>
		<idno type="ark">ark:/67375/HXZ-S93C7SKQ-5</idno>
		<idno type="istexId">AFF3E8A6A24F569DD3F0D513B4BEF550F827B942</idno>
		<ptr type="open-access" target="https://academic.oup.com/cid/article-pdf/33/5/700/1270065/33-5-700.pdf" />
	</analytic>
	<monogr>
		<title level="j">Clinical Infectious Diseases</title>
		<title level="j" type="abbrev">CLIN INFECT DIS</title>
		<idno type="ISSN">1058-4838</idno>
		<idno type="ISSNe">1537-6591</idno>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="700" to="705" />
			<date type="published" when="2001-09" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Average Adherence to Boosted Protease Inhibitor Therapy, rather than the Pattern of Missed Doses, as a Predictor of HIV RNA Replication</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jean‐jacques</forename><surname>Parienti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kathleen</forename><surname>Ragland</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Frédéric</forename><surname>Lucht</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arnaud</forename><surname>De La Blanchardière</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sylvie</forename><surname>Dargère</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yazdan</forename><surname>Yazdanpanah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jean‐jacques</forename><surname>Dutheil</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philippe</forename><surname>Perré</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Renaud</forename><surname>Verdon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">R</forename><surname>Bangsberg</surname></persName>
		</author>
		<idno type="DOI">10.1086/651419</idno>
		<idno type="PMID">20210643</idno>
		<idno type="PMCID">PMC3591724</idno>
		<idno type="ark">ark:/67375/HXZ-B6VRD7FM-T</idno>
		<idno type="istexId">09271B4A23C2C8320D281A85487B512DB148672E</idno>
		<ptr type="open-access" target="https://academic.oup.com/cid/article-pdf/50/8/1192/1232886/50-8-1192.pdf" />
	</analytic>
	<monogr>
		<title level="j">Clinical Infectious Diseases</title>
		<title level="j" type="abbrev">CLIN INFECT DIS</title>
		<idno type="ISSN">1058-4838</idno>
		<idno type="ISSNe">1537-6591</idno>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1192" to="1197" />
			<date type="published" when="2010-04-15" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">R</forename><surname>Bangsberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Frederick</forename><forename type="middle">M</forename><surname>Hecht</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Edwin</forename><forename type="middle">D</forename><surname>Charlebois</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">R</forename><surname>Zolopa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><surname>Holodniy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lewis</forename><surname>Sheiner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joshua</forename><forename type="middle">D</forename><surname>Bamberger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Margaret</forename><forename type="middle">A</forename><surname>Chesney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><surname>Moss</surname></persName>
		</author>
		<idno type="DOI">10.1097/00002030-200003100-00008</idno>
		<idno type="PMID">10770537</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS</title>
		<title level="j" type="abbrev">AIDS</title>
		<idno type="ISSN">0269-9370</idno>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="357" to="366" />
			<date type="published" when="2000-03" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Long-Term Efficacy of First Line Antiretroviral Therapy in Indian HIV-1 Infected Patients: A Longitudinal Cohort Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ujjwal</forename><surname>Neogi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elsa</forename><surname>Heylen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anita</forename><surname>Shet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sara</forename><surname>Chandy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ranjani</forename><surname>Shamsunder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anders</forename><surname>Sönnerborg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maria</forename><forename type="middle">L</forename><surname>Ekstrand</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0055421</idno>
		<idno type="PMID">23383185</idno>
		<idno type="PMCID">PMC3559582</idno>
		<ptr type="open-access" target="https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0055421&amp;type=printable" />
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<title level="j" type="abbrev">PLoS ONE</title>
		<idno type="ISSNe">1932-6203</idno>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">e55421</biblScope>
			<date type="published" when="2013-01-30" />
			<publisher>Public Library of Science (PLoS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jonathan</forename><forename type="middle">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roger</forename><surname>Paredes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Heather</forename><forename type="middle">J</forename><surname>Ribaudo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Evguenia</forename><forename type="middle">S</forename><surname>Svarovskaia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">J</forename><surname>Kozal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Katherine</forename><forename type="middle">H</forename><surname>Hullsiek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">D</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">R</forename><surname>Bangsberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daniel</forename><forename type="middle">R</forename><surname>Kuritzkes</surname></persName>
		</author>
		<idno type="DOI">10.1097/qad.0b013e32834e9d7d</idno>
		<idno type="PMID">22179227</idno>
		<idno type="PMCID">PMC3437231</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3437231?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">AIDS</title>
		<title level="j" type="abbrev">AIDS</title>
		<idno type="ISSN">0269-9370</idno>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="185" to="192" />
			<date type="published" when="2012-01" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maria</forename><forename type="middle">L</forename><surname>Ekstrand</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anita</forename><surname>Shet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sara</forename><surname>Chandy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Girija</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ranjani</forename><surname>Shamsundar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vidya</forename><surname>Madhavan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shanmugam</forename><surname>Saravanan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elsa</forename><surname>Heylen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nagalingeswaran</forename><surname>Kumarasamy</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.inhe.2010.11.003</idno>
		<idno type="PMID">21516199</idno>
		<idno type="PMCID">PMC3079268</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3079268?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">International Health</title>
		<title level="j" type="abbrev">International Health</title>
		<idno type="ISSN">1876-3413</idno>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="27" to="34" />
			<date type="published" when="2011-03" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Adherence to Triple Therapy and Viral Load Response</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sophie</forename><surname>Low-Beer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Benita</forename><surname>Yip</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">V</forename><surname>O'shaughnessy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">S</forename><surname>Hogg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julio</forename><forename type="middle">S G</forename><surname>Montaner</surname></persName>
		</author>
		<idno type="DOI">10.1097/00042560-200004010-00016</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Acquired Immune Deficiency Syndromes</title>
		<title level="j" type="abbrev">Journal of Acquired Immune Deficiency Syndromes</title>
		<idno type="ISSN">1525-4135</idno>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="360" to="361" />
			<date type="published" when="2000-04" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chuka</forename><forename type="middle">J</forename><surname>Anude</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Emeka</forename><surname>Eze</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Henry</forename><forename type="middle">C</forename><surname>Onyegbutulem</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Man</forename><surname>Charurat</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mary-Ann</forename><surname>Etiebet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Samuel</forename><surname>Ajayi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Patrick</forename><surname>Dakum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Oluyemisi</forename><surname>Akinwande</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chris</forename><surname>Beyrer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alash’le</forename><surname>Abimiku</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">William</forename><surname>Blattner</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2334-13-113</idno>
		<idno type="PMID">23452915</idno>
		<idno type="PMCID">PMC3599241</idno>
		<ptr type="open-access" target="https://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/1471-2334-13-113" />
	</analytic>
	<monogr>
		<title level="j">BMC Infectious Diseases</title>
		<title level="j" type="abbrev">BMC Infect Dis</title>
		<idno type="ISSNe">1471-2334</idno>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">113</biblScope>
			<date type="published" when="2013-03-01" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Characterizing HIV Medication Adherence for Virologic Success Among Individuals Living With HIV/AIDS: Experience With the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Cohort</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bipasha</forename><surname>Biswas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Edward</forename><surname>Spitznagel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ann</forename><forename type="middle">C</forename><surname>Collier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Benjamin</forename><forename type="middle">B</forename><surname>Gelman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Justin</forename><forename type="middle">C</forename><surname>Mcarthur</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susan</forename><surname>Morgello</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">Allen</forename><surname>Mccutchan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">B</forename><surname>Clifford</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>The Charter Group</surname></persName>
		</author>
		<idno type="DOI">10.1080/15381501.2013.859111</idno>
		<idno type="PMID">24678283</idno>
		<idno type="PMCID">PMC3963153</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3963153?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Journal of HIV/AIDS &amp; Social Services</title>
		<title level="j" type="abbrev">Journal of HIV/AIDS &amp; Social Services</title>
		<idno type="ISSN">1538-1501</idno>
		<idno type="ISSNe">1538-151X</idno>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="8" to="25" />
			<date type="published" when="2014-01" />
			<publisher>Informa UK Limited</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Suboptimal plasma HIV-1 RNA suppression and adherence among sex workers who use illicit drugs in a Canadian setting: an observational cohort study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lianping</forename><surname>Ti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M-J</forename><surname>Milloy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kate</forename><surname>Shannon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Annick</forename><surname>Simo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">S</forename><surname>Hogg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sylvia</forename><surname>Guillemi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julio</forename><surname>Montaner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thomas</forename><surname>Kerr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Evan</forename><surname>Wood</surname></persName>
		</author>
		<idno type="DOI">10.1136/sextrans-2013-051408</idno>
		<idno type="PMID">24523347</idno>
		<idno type="PMCID">PMC4102614</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc4102614?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Sexually Transmitted Infections</title>
		<title level="j" type="abbrev">Sex Transm Infect</title>
		<idno type="ISSN">1368-4973</idno>
		<idno type="ISSNe">1472-3263</idno>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="418" to="422" />
			<date type="published" when="2014-02-12" />
			<publisher>BMJ</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ziad</forename><surname>El-Khatib</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><forename type="middle">Mia</forename><surname>Ekstrom</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ashraf</forename><surname>Coovadia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elaine</forename><forename type="middle">J</forename><surname>Abrams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Max</forename><surname>Petzold</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Katzenstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lynn</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Louise</forename><surname>Kuhn</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2458-11-88</idno>
		<idno type="PMID">21303548</idno>
		<idno type="PMCID">PMC3046911</idno>
		<ptr type="open-access" target="https://bmcpublichealth.biomedcentral.com/track/pdf/10.1186/1471-2458-11-88" />
	</analytic>
	<monogr>
		<title level="j">BMC Public Health</title>
		<title level="j" type="abbrev">BMC Public Health</title>
		<idno type="ISSNe">1471-2458</idno>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">88</biblScope>
			<date type="published" when="2011-02-08" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Correlates of Self-Reported Nonadherence to Antiretroviral Therapy in HIV-Infected Patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tracy</forename><forename type="middle">R</forename><surname>Glass</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sabina</forename><surname>De Geest</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rainer</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pietro</forename><forename type="middle">L</forename><surname>Vernazza</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Rickenbach</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hansjakob</forename><surname>Furrer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Enos</forename><surname>Bernasconi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthias</forename><surname>Cavassini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bernard</forename><surname>Hirschel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Manuel</forename><surname>Battegay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Heiner</forename><forename type="middle">C</forename><surname>Bucher</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.qai.0000186371.95301.52</idno>
		<idno type="PMID">16540942</idno>
	</analytic>
	<monogr>
		<title level="j">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<title level="j" type="abbrev">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<idno type="ISSN">1525-4135</idno>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="385" to="392" />
			<date type="published" when="2006-03" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Correlates of HIV-1 viral suppression in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">R</forename><surname>Jordan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>La</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">D</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Sheehan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">T M</forename><surname>Lien</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">V</forename><surname>Duong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Hellinger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Wanke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Tang</surname></persName>
		</author>
		<idno type="DOI">10.1258/ijsa.2008.008389</idno>
		<idno type="PMID">19451329</idno>
		<idno type="PMCID">PMC2887676</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc2887676?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">International Journal of STD &amp; AIDS</title>
		<title level="j" type="abbrev">Int J STD AIDS</title>
		<idno type="ISSN">0956-4624</idno>
		<idno type="ISSNe">1758-1052</idno>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="418" to="422" />
			<date type="published" when="2009-06" />
			<publisher>SAGE Publications</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Simple Adherence Assessments to Predict Virologic Failure among HIV-Infected Adults with Discordant Immunologic and Clinical Responses to Antiretroviral Therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jason</forename><forename type="middle">D</forename><surname>Goldman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ronald</forename><forename type="middle">A</forename><surname>Cantrell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lloyd</forename><forename type="middle">B</forename><surname>Mulenga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bushimbwa</forename><forename type="middle">C</forename><surname>Tambatamba</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stewart</forename><forename type="middle">E</forename><surname>Reid</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jens</forename><forename type="middle">W</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mohammed</forename><surname>Limbada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Angela</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">S</forename><surname>Saag</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sten</forename><forename type="middle">H</forename><surname>Vermund</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeffrey</forename><forename type="middle">S A</forename><surname>Stringer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Benjamin</forename><forename type="middle">H</forename><surname>Chi</surname></persName>
		</author>
		<idno type="DOI">10.1089/aid.2008.0035</idno>
		<idno type="PMID">18724803</idno>
		<idno type="PMCID">PMC2747786</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS Research and Human Retroviruses</title>
		<title level="j" type="abbrev">AIDS Research and Human Retroviruses</title>
		<idno type="ISSN">0889-2229</idno>
		<idno type="ISSNe">1931-8405</idno>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1031" to="1035" />
			<date type="published" when="2008-08" />
			<publisher>Mary Ann Liebert Inc</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><surname>Court</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rory</forename><surname>Leisegang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Annemie</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Henry</forename><surname>Sunpath</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philip</forename><surname>Winternheimer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mashuda</forename><surname>Ally</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gary</forename><surname>Maartens</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12879-014-0664-3</idno>
		<idno type="PMID">25472544</idno>
		<idno type="PMCID">PMC4266950</idno>
		<ptr type="open-access" target="https://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/s12879-014-0664-3" />
	</analytic>
	<monogr>
		<title level="j">BMC Infectious Diseases</title>
		<title level="j" type="abbrev">BMC Infect Dis</title>
		<idno type="ISSNe">1471-2334</idno>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">664</biblScope>
			<date type="published" when="2014-12" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Impact of early versus late adherence to highly active antiretroviral therapy on immunovirological response: a 3-year follow-up study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">P</forename><surname>Carrieri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Raffi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Lewden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antivir Ther</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="585" to="594" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Modest Nonadherence to Antiretroviral Therapy Promotes Residual HIV-1 Replication in the Absence of Virological Rebound in Plasma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alexander</forename><forename type="middle">O</forename><surname>Pasternak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marijn</forename><surname>De Bruin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Suzanne</forename><surname>Jurriaans</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Margreet</forename><surname>Bakker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ben</forename><surname>Berkhout</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jan</forename><forename type="middle">M</forename><surname>Prins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vladimir</forename><forename type="middle">V</forename><surname>Lukashov</surname></persName>
		</author>
		<idno type="DOI">10.1093/infdis/jis502</idno>
		<idno type="PMID">22927449</idno>
		<ptr type="open-access" target="https://academic.oup.com/jid/article-pdf/206/9/1443/13803631/jis502.pdf" />
	</analytic>
	<monogr>
		<title level="j">The Journal of Infectious Diseases</title>
		<idno type="ISSN">0022-1899</idno>
		<idno type="ISSNe">1537-6613</idno>
		<imprint>
			<biblScope unit="volume">206</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1443" to="1452" />
			<date type="published" when="2012-08-20" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">CD4, Viral Load Response, and Adherence Among Antiretroviral-Naive Breast-feeding Women Receiving Triple Antiretroviral Prophylaxis for Prevention of Mother-to-Child Transmission of HIV in Kisumu, Kenya</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jully</forename><forename type="middle">A</forename><surname>Okonji</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Clement</forename><surname>Zeh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><forename type="middle">J</forename><surname>Weidle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Benta</forename><surname>Akoth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rose</forename><forename type="middle">O</forename><surname>Masaba</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mary</forename><forename type="middle">G</forename><surname>Fowler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Timothy</forename><forename type="middle">K</forename><surname>Thomas</surname></persName>
		</author>
		<idno type="DOI">10.1097/qai.0b013e318262514f</idno>
		<idno type="PMID">22692094</idno>
	</analytic>
	<monogr>
		<title level="j">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<title level="j" type="abbrev">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<idno type="ISSN">1525-4135</idno>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="249" to="257" />
			<date type="published" when="2012-10" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pedro</forename><surname>Cahn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Asda</forename><surname>Vibhagool</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mauro</forename><surname>Schechter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Luis</forename><surname>Soto-Ramirez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giampiero</forename><surname>Carosi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fiona</forename><surname>Smaill</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jamie</forename><forename type="middle">C</forename><surname>Jordan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cristina</forename><forename type="middle">E</forename><surname>Pharo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nicola</forename><forename type="middle">E</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Helen</forename><forename type="middle">M</forename><surname>Steel</surname></persName>
		</author>
		<idno type="DOI">10.1185/030079904125004051</idno>
		<idno type="PMID">15265256</idno>
	</analytic>
	<monogr>
		<title level="j">Current Medical Research and Opinion</title>
		<title level="j" type="abbrev">Current Medical Research and Opinion</title>
		<idno type="ISSN">0300-7995</idno>
		<idno type="ISSNe">1473-4877</idno>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1115" to="1123" />
			<date type="published" when="2004-06-02" />
			<publisher>Informa Healthcare</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Prospective Randomized Two-Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long-Term Adherence to Highly Active Antiretroviral Therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Albert</forename><surname>Tuldrà</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carmina</forename><forename type="middle">R</forename><surname>Fumaz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ma</forename><forename type="middle">José</forename><surname>Ferrer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ramon</forename><surname>Bayés</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Albert</forename><surname>Arnó</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Montserrat</forename><surname>Balagué</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><surname>Bonjoch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Antoni</forename><surname>Jou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eugènia</forename><surname>Negredo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roger</forename><surname>Paredes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lidia</forename><surname>Ruiz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joan</forename><surname>Romeu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guillem</forename><surname>Sirera</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cristina</forename><surname>Tural</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Burger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bonaventura</forename><surname>Clotet</surname></persName>
		</author>
		<idno type="DOI">10.1097/00126334-200011010-00003</idno>
		<idno type="PMID">11115952</idno>
	</analytic>
	<monogr>
		<title level="j">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<title level="j" type="abbrev">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<idno type="ISSN">1525-4135</idno>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="221" to="228" />
			<date type="published" when="2000-11" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mégane</forename><surname>Meresse</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maria</forename><forename type="middle">Patrizia</forename><surname>Carrieri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christian</forename><surname>Laurent</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Charles</forename><surname>Kouanfack</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Camelia</forename><surname>Protopopescu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jérôme</forename><surname>Blanche</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julien</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gabrièle</forename><surname>Laborde-Balen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Avelin</forename><forename type="middle">F</forename><surname>Aghokeng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bruno</forename><surname>Spire</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jean-Paul</forename><surname>Moatti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eric</forename><surname>Delaporte</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sylvie</forename><surname>Boyer</surname></persName>
		</author>
		<idno type="DOI">10.3851/imp2535</idno>
		<idno type="PMID">23358393</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/bcb8/a2f4b88d3efbe722a473936a2e71af1a69ce.pdf" />
	</analytic>
	<monogr>
		<title level="j">Antiviral Therapy</title>
		<title level="j" type="abbrev">Antivir Ther</title>
		<idno type="ISSN">1359-6535</idno>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="29" to="37" />
			<date type="published" when="2013" />
			<publisher>International Medical Press</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><surname>Carr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><surname>Chuah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeff</forename><surname>Hudson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martyn</forename><surname>French</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jennifer</forename><surname>Hoy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthew</forename><surname>Law</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Sayer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sean</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">A</forename><surname>Cooper</surname></persName>
		</author>
		<idno type="DOI">10.1097/00002030-200006160-00014</idno>
		<idno type="PMID">10894281</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS</title>
		<title level="j" type="abbrev">AIDS</title>
		<idno type="ISSN">0269-9370</idno>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1171" to="1180" />
			<date type="published" when="2000-06" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Calvin</forename><forename type="middle">J</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jean-Michel</forename><surname>Molina</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Isabel</forename><surname>Cassetti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ploenchan</forename><surname>Chetchotisakd</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Adriano</forename><surname>Lazzarin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chloe</forename><surname>Orkin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Frank</forename><surname>Rhame</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hans-Jürgen</forename><surname>Stellbrink</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Taisheng</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Herta</forename><surname>Crauwels</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Laurence</forename><surname>Rimsky</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Simon</forename><surname>Vanveggel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Katia</forename><surname>Boven</surname></persName>
		</author>
		<idno type="DOI">10.1097/qad.0b013e32835cee6e</idno>
		<idno type="PMID">23211772</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS</title>
		<title level="j" type="abbrev">AIDS</title>
		<idno type="ISSN">0269-9370</idno>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="939" to="950" />
			<date type="published" when="2013-03" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">H</forename><surname>Haubrich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susan</forename><forename type="middle">J</forename><surname>Little</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Judith</forename><forename type="middle">S</forename><surname>Currier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Donald</forename><forename type="middle">N</forename><surname>Forthal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carol</forename><forename type="middle">A</forename><surname>Kemper</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gildon</forename><forename type="middle">N</forename><surname>Beall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Debra</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">P</forename><surname>Dubé</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jimmy</forename><forename type="middle">Y</forename><surname>Hwanga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">Allen</forename><surname>Mccutchan</surname></persName>
		</author>
		<idno type="DOI">10.1097/00002030-199906180-00014</idno>
		<idno type="PMID">10397541</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS</title>
		<title level="j" type="abbrev">AIDS</title>
		<idno type="ISSN">0269-9370</idno>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1099" to="1107" />
			<date type="published" when="1999-06" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Patterns of Individual and Population-Level Adherence to Antiretroviral Therapy and Risk Factors for Poor Adherence in the First Year of the DART Trial in Uganda and Zimbabwe</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sylvia</forename><forename type="middle">K</forename><surname>Muyingo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">Sarah</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andy</forename><surname>Reid</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paula</forename><surname>Munderi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Diana</forename><forename type="middle">M</forename><surname>Gibb</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Francis</forename><surname>Ssali</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jonathan</forename><surname>Levin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elly</forename><surname>Katabira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Charlie</forename><surname>Gilks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jim</forename><surname>Todd</surname></persName>
		</author>
		<idno type="DOI">10.1097/qai.0b013e31817dc3fd</idno>
		<idno type="PMID">18614918</idno>
	</analytic>
	<monogr>
		<title level="j">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<title level="j" type="abbrev">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<idno type="ISSN">1525-4135</idno>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="468" to="475" />
			<date type="published" when="2008-08" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P-M</forename><surname>Girard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Demasi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Smets</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Sekar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Lavreys</surname></persName>
		</author>
		<idno type="DOI">10.1093/jac/dkq150</idno>
		<idno type="PMID">20498120</idno>
		<idno type="ark">ark:/67375/HXZ-RZNBD89G-S</idno>
		<idno type="istexId">D4FFBE9CE60BD377E80FB19EA341D2A97880133B</idno>
		<ptr type="open-access" target="https://academic.oup.com/jac/article-pdf/65/7/1505/2369615/dkq150.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Antimicrobial Chemotherapy</title>
		<title level="j" type="abbrev">Journal of Antimicrobial Chemotherapy</title>
		<idno type="ISSN">0305-7453</idno>
		<idno type="ISSNe">1460-2091</idno>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1505" to="1509" />
			<date type="published" when="2010-05-24" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Effect of mobile telephone reminders on treatment outcome in HIV: evidence from a randomised controlled trial in India</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Shet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">D</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Kumarasamy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Rodrigues</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">B</forename><surname>Rewari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Ashorn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Eriksson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Diwan</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.g5978</idno>
		<idno type="PMID">25742320</idno>
		<idno type="PMCID">PMC4459037</idno>
		<ptr type="open-access" target="https://www.bmj.com/content/349/bmj.g5978.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<title level="j" type="abbrev">BMJ</title>
		<idno type="ISSNe">1756-1833</idno>
		<imprint>
			<biblScope unit="volume">347</biblScope>
			<biblScope unit="issue">aug06 2</biblScope>
			<biblScope unit="page" from="g5978" to="g5978" />
			<date type="published" when="2014-10-24" />
			<publisher>BMJ</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Second-line antiretroviral therapy: long-term outcomes in South Africa</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Sunpath</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Castilla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Acquir Immune Defic Syndr</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="158" to="163" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seonaid</forename><surname>Nolan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M-J</forename><surname>Milloy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ruth</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thomas</forename><surname>Kerr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">S</forename><surname>Hogg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julio</forename><forename type="middle">S G</forename><surname>Montaner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Evan</forename><surname>Wood</surname></persName>
		</author>
		<idno type="DOI">10.1080/09540121.2010.543882</idno>
		<idno type="PMID">21480010</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS Care</title>
		<title level="j" type="abbrev">AIDS Care</title>
		<idno type="ISSN">0954-0121</idno>
		<idno type="ISSNe">1360-0451</idno>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="980" to="987" />
			<date type="published" when="2011-04-08" />
			<publisher>Informa UK Limited</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Adherence to Drug-Refill Is a Useful Early Warning Indicator of Virologic and Immunologic Failure among HIV Patients on First-Line ART in South Africa</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ziad</forename><surname>El-Khatib</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Katzenstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gaetano</forename><surname>Marrone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fatima</forename><surname>Laher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lerato</forename><surname>Mohapi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Max</forename><surname>Petzold</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lynn</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><forename type="middle">Mia</forename><surname>Ekström</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0017518</idno>
		<idno type="PMID">21408071</idno>
		<idno type="PMCID">PMC3052314</idno>
		<ptr type="open-access" target="https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0017518&amp;type=printable" />
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<title level="j" type="abbrev">PLoS ONE</title>
		<idno type="ISSNe">1932-6203</idno>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">e17518</biblScope>
			<date type="published" when="2011-03-09" />
			<publisher>Public Library of Science (PLoS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Risk of Viral Failure Declines With Duration of Suppression on Highly Active Antiretroviral Therapy Irrespective of Adherence Level</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Viviane</forename><forename type="middle">D</forename><surname>Lima</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">R</forename><surname>Bangsberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">Richard</forename><surname>Harrigan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steven</forename><forename type="middle">G</forename><surname>Deeks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Benita</forename><surname>Yip</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">S</forename><surname>Hogg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julio</forename><forename type="middle">S G</forename><surname>Montaner</surname></persName>
		</author>
		<idno type="DOI">10.1097/qai.0b013e3181f2ac87</idno>
		<idno type="PMID">20838225</idno>
		<idno type="PMCID">PMC2974791</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc2974791?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<title level="j" type="abbrev">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<idno type="ISSN">1525-4135</idno>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="460" to="465" />
			<date type="published" when="2010-12" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mari</forename><forename type="middle">M</forename><surname>Kitahata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shelby</forename><forename type="middle">D</forename><surname>Reed</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><forename type="middle">W</forename><surname>Dillingham</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephen</forename><forename type="middle">E</forename><surname>Van Rompaey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alicia</forename><forename type="middle">A</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">D</forename><surname>Harrington</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">King</forename><forename type="middle">K</forename><surname>Holmes</surname></persName>
		</author>
		<idno type="DOI">10.1258/0956462042563666</idno>
		<idno type="PMID">15601487</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of STD &amp; AIDS</title>
		<title level="j" type="abbrev">Int J STD AIDS</title>
		<idno type="ISSN">0956-4624</idno>
		<idno type="ISSNe">1758-1052</idno>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="803" to="810" />
			<date type="published" when="2004-12" />
			<publisher>SAGE Publications</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Clinical Utility of Pharmacy-Based Adherence Measurement in Predicting Virologic Outcomes in an Adult HIV-Infected Cohort in Jos, North Central Nigeria</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Isaac</forename><forename type="middle">Okoh</forename><surname>Abah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Victor</forename><forename type="middle">Bazim</forename><surname>Ojeh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jonah</forename><surname>Musa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Placid</forename><surname>Ugoagwu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Patricia</forename><forename type="middle">Aladi</forename><surname>Agaba</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Oche</forename><surname>Agbaji</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Prosper</forename><surname>Okonkwo</surname></persName>
		</author>
		<idno type="DOI">10.1177/2325957414539197</idno>
		<idno type="PMID">24963086</idno>
		<ptr type="open-access" target="https://journals.sagepub.com/doi/pdf/10.1177/2325957414539197" />
	</analytic>
	<monogr>
		<title level="j">Journal of the International Association of Providers of AIDS Care (JIAPAC)</title>
		<title level="j" type="abbrev">Journal of the International Association of Providers of AIDS Care (JIAPAC)</title>
		<idno type="ISSN">2325-9574</idno>
		<idno type="ISSNe">2325-9582</idno>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="77" to="83" />
			<date type="published" when="2014-06-24" />
			<publisher>SAGE Publications</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Pharmacy and Self-Report Adherence Measures to Predict Virological Outcomes for Patients on Free Antiretroviral Therapy in Tamil Nadu, India</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><forename type="middle">H</forename><surname>Mcmahon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anand</forename><surname>Manoharan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christine</forename><forename type="middle">A</forename><surname>Wanke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shoba</forename><surname>Mammen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hepsibah</forename><surname>Jose</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thabeetha</forename><surname>Malini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tony</forename><surname>Kadavanu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">R</forename><surname>Jordan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julian</forename><forename type="middle">H</forename><surname>Elliott</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sharon</forename><forename type="middle">R</forename><surname>Lewin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dilip</forename><surname>Mathai</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10461-013-0436-x</idno>
		<idno type="PMID">23435750</idno>
		<idno type="PMCID">PMC3674125</idno>
		<idno type="ark">ark:/67375/VQC-B3V3K3NQ-7</idno>
		<idno type="istexId">3EC98DE3CCB1D4FC3ED0273A80B609CB5F780DD7</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3674125?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">AIDS and Behavior</title>
		<title level="j" type="abbrev">AIDS Behav</title>
		<idno type="ISSN">1090-7165</idno>
		<idno type="ISSNe">1573-3254</idno>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2253" to="2259" />
			<date type="published" when="2013-02-24" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Adherence to Highly Active Antiretroviral Therapy (HAART): A Meta-Analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carmen</forename><surname>Ortego</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tania</forename><forename type="middle">B</forename><surname>Huedo-Medina</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Javier</forename><surname>Llorca</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lourdes</forename><surname>Sevilla</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pilar</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elías</forename><surname>Rodríguez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michelle</forename><forename type="middle">R</forename><surname>Warren</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Javier</forename><surname>Vejo</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10461-011-9942-x</idno>
		<idno type="PMID">21468660</idno>
		<idno type="ark">ark:/67375/VQC-N7ZRBM6N-1</idno>
		<idno type="istexId">358828DA2EE4454C8EF503BB10B0DBE7C559C3C7</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS and Behavior</title>
		<title level="j" type="abbrev">AIDS Behav</title>
		<idno type="ISSN">1090-7165</idno>
		<idno type="ISSNe">1573-3254</idno>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1381" to="1396" />
			<date type="published" when="2011-04-06" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Antiretroviral adherence interventions: a review of current literature and ongoing studies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Simoni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">A</forename><surname>Frick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">W</forename><surname>Pantalone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Top HIV Med</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="185" to="198" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">A Meta-Analysis of Adherence to Antiretroviral Therapy and Virologic Responses in HIV-Infected Children, Adolescents, and Young Adults</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shoshana</forename><forename type="middle">Y</forename><surname>Kahana</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jennifer</forename><surname>Rohan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susannah</forename><surname>Allison</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thomas</forename><forename type="middle">W</forename><surname>Frazier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dennis</forename><surname>Drotar</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10461-012-0159-4</idno>
		<idno type="PMID">22411426</idno>
		<idno type="ark">ark:/67375/VQC-8BTLHK25-6</idno>
		<idno type="istexId">EBDDB017D5549841A04466ADE827B86CC782E65D</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS and Behavior</title>
		<title level="j" type="abbrev">AIDS Behav</title>
		<idno type="ISSN">1090-7165</idno>
		<idno type="ISSNe">1573-3254</idno>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="41" to="60" />
			<date type="published" when="2012-03-13" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><surname>Rosenblum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steven</forename><forename type="middle">G</forename><surname>Deeks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><surname>Van Der Laan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">R</forename><surname>Bangsberg</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0007196</idno>
		<idno type="PMID">19787058</idno>
		<idno type="PMCID">PMC2747009</idno>
		<ptr type="open-access" target="https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0007196&amp;type=printable" />
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<title level="j" type="abbrev">PLoS ONE</title>
		<idno type="ISSNe">1932-6203</idno>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">e7196</biblScope>
			<date type="published" when="2009-09-29" />
			<publisher>Public Library of Science (PLoS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shilpa</forename><surname>Viswanathan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Amy</forename><forename type="middle">C</forename><surname>Justice</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">Caleb</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Todd</forename><forename type="middle">T</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Neel</forename><forename type="middle">R</forename><surname>Gandhi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ian</forename><forename type="middle">R</forename><surname>Mcnicholl</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Rimland</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maria</forename><forename type="middle">C</forename><surname>Rodriguez-Barradas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lisa</forename><forename type="middle">P</forename><surname>Jacobson</surname></persName>
		</author>
		<idno type="DOI">10.1097/qai.0000000000000643</idno>
		<idno type="PMID">25886923</idno>
		<idno type="PMCID">PMC4482798</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc4482798?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<title level="j" type="abbrev">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<idno type="ISSN">1525-4135</idno>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="493" to="498" />
			<date type="published" when="2015-08" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Is the Influence of Social Desirability on Patients&apos; Self-Reported Adherence Overrated?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Glenn</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Loren</forename><forename type="middle">G</forename><surname>Miller</surname></persName>
		</author>
		<idno type="DOI">10.1097/00126334-200402010-00016</idno>
		<idno type="PMID">14722455</idno>
	</analytic>
	<monogr>
		<title level="j">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<title level="j" type="abbrev">JAIDS Journal of Acquired Immune Deficiency Syndromes</title>
		<idno type="ISSN">1525-4135</idno>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="203" to="204" />
			<date type="published" when="2004-02" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Less Than 95% Adherence to Nonnucleoside Reverse‐Transcriptase Inhibitor Therapy Can Lead to Viral Suppression</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">R</forename><surname>Bangsberg</surname></persName>
		</author>
		<idno type="DOI">10.1086/507526</idno>
		<idno type="PMID">16941380</idno>
		<idno type="ark">ark:/67375/HXZ-RGSRPZPD-3</idno>
		<idno type="istexId">78E1541BE78A40A2F8F39756A6BE6D7AE92AAD44</idno>
		<ptr type="open-access" target="https://academic.oup.com/cid/article-pdf/43/7/939/1058318/43-7-939.pdf" />
	</analytic>
	<monogr>
		<title level="j">Clinical Infectious Diseases</title>
		<title level="j" type="abbrev">CLIN INFECT DIS</title>
		<idno type="ISSN">1058-4838</idno>
		<idno type="ISSNe">1537-6591</idno>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="939" to="941" />
			<date type="published" when="2006-10" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Adherence to Antiretroviral Therapy in Sub-Saharan Africa and North America</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Edward</forename><forename type="middle">J</forename><surname>Mills</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jean</forename><forename type="middle">B</forename><surname>Nachega</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Iain</forename><surname>Buchan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><surname>Orbinski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Amir</forename><surname>Attaran</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sonal</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Beth</forename><surname>Rachlis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ping</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Curtis</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lehana</forename><surname>Thabane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kumanan</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gordon</forename><forename type="middle">H</forename><surname>Guyatt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">R</forename><surname>Bangsberg</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.296.6.679</idno>
		<idno type="PMID">16896111</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<title level="j" type="abbrev">JAMA</title>
		<idno type="ISSN">0098-7484</idno>
		<imprint>
			<biblScope unit="volume">296</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page">679</biblScope>
			<date type="published" when="2006-08-09" />
			<publisher>American Medical Association (AMA)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ravindra</forename><forename type="middle">K</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">R</forename><surname>Jordan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Binta</forename><forename type="middle">J</forename><surname>Sultan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daniel</forename><forename type="middle">Hj</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><surname>Gregson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anthony</forename><forename type="middle">W</forename><surname>Sawyer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Raph</forename><forename type="middle">L</forename><surname>Hamers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nicaise</forename><surname>Ndembi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Deenan</forename><surname>Pillay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Silvia</forename><surname>Bertagnolio</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(12)61038-1</idno>
		<idno type="PMID">22828485</idno>
		<idno type="PMCID">PMC3790969</idno>
		<ptr type="open-access" target="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790969/pdf" />
	</analytic>
	<monogr>
		<title level="j">The Lancet</title>
		<title level="j" type="abbrev">The Lancet</title>
		<idno type="ISSN">0140-6736</idno>
		<imprint>
			<biblScope unit="volume">380</biblScope>
			<biblScope unit="issue">9849</biblScope>
			<biblScope unit="page" from="1250" to="1258" />
			<date type="published" when="2012-10" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">F</forename><surname>Gunthard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Aberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Eron</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">312</biblScope>
			<biblScope unit="page" from="410" to="425" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andreas</forename><forename type="middle">D</forename><surname>Haas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Olivia</forename><surname>Keiser</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eric</forename><surname>Balestre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steve</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Emmanuel</forename><surname>Bissagnene</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cleophas</forename><surname>Chimbetete</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">François</forename><surname>Dabis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mary-Ann</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christopher</forename><forename type="middle">J</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Patrick</forename><surname>Oyaro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rosalind</forename><surname>Parkes-Ratanshi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steven</forename><forename type="middle">J</forename><surname>Reynolds</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Izukanji</forename><surname>Sikazwe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kara</forename><surname>Wools-Kaloustian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">Marcel</forename><surname>Zannou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gilles</forename><surname>Wandeler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthias</forename><surname>Egger</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2352-3018(15)00087-9</idno>
		<idno type="PMID">26423252</idno>
		<idno type="PMCID">PMC4500741</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc4500741?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">The Lancet HIV</title>
		<title level="j" type="abbrev">The Lancet HIV</title>
		<idno type="ISSN">2352-3018</idno>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="e271" to="e278" />
			<date type="published" when="2015-07" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Comparison of Evidence of Treatment Effects in Randomized and Nonrandomized Studies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">P</forename><surname>Ioannidis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A-B</forename><surname>Haidich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Pappa</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.286.7.821</idno>
		<idno type="PMID">11497536</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<title level="j" type="abbrev">JAMA</title>
		<idno type="ISSN">0098-7484</idno>
		<imprint>
			<biblScope unit="volume">286</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">821</biblScope>
			<date type="published" when="2001-08-15" />
			<publisher>American Medical Association (AMA)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Survivor Treatment Selection Bias in Observational Studies: Examples from the AIDS Literature</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marshall</forename><forename type="middle">J</forename><surname>Glesby</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">R</forename><surname>Hoover</surname></persName>
		</author>
		<idno type="DOI">10.7326/0003-4819-124-11-199606010-00008</idno>
		<idno type="PMID">8624068</idno>
	</analytic>
	<monogr>
		<title level="j">Annals of Internal Medicine</title>
		<title level="j" type="abbrev">Ann Intern Med</title>
		<idno type="ISSN">0003-4819</idno>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page">999</biblScope>
			<date type="published" when="1996-06-01" />
			<publisher>American College of Physicians</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
